Trial Profile
A phase III study of AVP-923 for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2015
Price :
$35
*
At a glance
- Drugs Dextromethorphan/quinidine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 25 Sep 2015 New trial record
- 22 Sep 2015 According to Avanir Pharmaceuticals media release, company is planning to start this program called TRIAD later this year